197 related articles for article (PubMed ID: 32652197)
1. Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us?
Liu C; Ma X; Zhuang J; Liu L; Sun C
Pharmacol Res; 2020 Oct; 160():105062. PubMed ID: 32652197
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective Potentials of Plant-Derived Small Molecules against Doxorubicin Associated Cardiotoxicity.
Ojha S; Al Taee H; Goyal S; Mahajan UB; Patil CR; Arya DS; Rajesh M
Oxid Med Cell Longev; 2016; 2016():5724973. PubMed ID: 27313831
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity.
Abushouk AI; Ismail A; Salem AMA; Afifi AM; Abdel-Daim MM
Biomed Pharmacother; 2017 Jun; 90():935-946. PubMed ID: 28460429
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-induced Cardiotoxicity and Cardioprotective Agents: Classic and New Players in the Game.
Dos Santos Arruda F; Tomé FD; Miguel MP; de Menezes LB; Nagib PRA; Campos EC; Soave DF; Celes MRN
Curr Pharm Des; 2019; 25(2):109-118. PubMed ID: 30864503
[TBL] [Abstract][Full Text] [Related]
5. Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity.
Koleini N; Kardami E
Oncotarget; 2017 Jul; 8(28):46663-46680. PubMed ID: 28445146
[TBL] [Abstract][Full Text] [Related]
6. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.
Ruggeri C; Gioffré S; Achilli F; Colombo GI; D'Alessandra Y
Heart Fail Rev; 2018 Jan; 23(1):109-122. PubMed ID: 28944400
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of doxorubicin-induced cardiotoxicity: novel roles of sirtuin 1-mediated signaling pathways.
Wang A J; Zhang J; Xiao M; Wang S; Wang B J; Guo Y; Tang Y; Gu J
Cell Mol Life Sci; 2021 Apr; 78(7):3105-3125. PubMed ID: 33438055
[TBL] [Abstract][Full Text] [Related]
8. Alternative approach for mitigation of doxorubicin-induced cardiotoxicity using herbal agents.
Khan MA; Singh M; Khan MS; Ahmad W; Najmi AK; Ahmad S
Curr Clin Pharmacol; 2014; 9(3):288-97. PubMed ID: 23342982
[TBL] [Abstract][Full Text] [Related]
9. Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect.
Ma P; Qin Y; Cao H; Erben U; Ni C; Qin Z
Biomed Pharmacother; 2020 Oct; 130():110587. PubMed ID: 32763819
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin.
Hallman BE; Hauck ML; Williams LE; Hess PR; Suter SE
J Vet Intern Med; 2019 Mar; 33(2):783-791. PubMed ID: 30697816
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity.
Liu H; Wang H; Xiang D; Guo W
Mini Rev Med Chem; 2017; 17(1):44-50. PubMed ID: 27337969
[TBL] [Abstract][Full Text] [Related]
12. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death.
Kong CY; Guo Z; Song P; Zhang X; Yuan YP; Teng T; Yan L; Tang QZ
Int J Biol Sci; 2022; 18(2):760-770. PubMed ID: 35002523
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
[TBL] [Abstract][Full Text] [Related]
15. VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.
Räsänen M; Degerman J; Nissinen TA; Miinalainen I; Kerkelä R; Siltanen A; Backman JT; Mervaala E; Hulmi JJ; Kivelä R; Alitalo K
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13144-13149. PubMed ID: 27799559
[TBL] [Abstract][Full Text] [Related]
16. A review on the cardioprotective mechanisms of metformin against doxorubicin.
Ajzashokouhi AH; Bostan HB; Jomezadeh V; Hayes AW; Karimi G
Hum Exp Toxicol; 2020 Mar; 39(3):237-248. PubMed ID: 31735071
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of Doxorubicin (Dox) to different experimental organ systems.
Pugazhendhi A; Edison TNJI; Velmurugan BK; Jacob JA; Karuppusamy I
Life Sci; 2018 May; 200():26-30. PubMed ID: 29534993
[TBL] [Abstract][Full Text] [Related]
18. Alternate-day fasting exacerbates doxorubicin cardiotoxicity in cancer chemotherapy.
Pan H; Yang S; Cheng W; Cai Q; Shubhra QTH
Trends Endocrinol Metab; 2023 Jul; 34(7):392-394. PubMed ID: 37246117
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management.
Rawat PS; Jaiswal A; Khurana A; Bhatti JS; Navik U
Biomed Pharmacother; 2021 Jul; 139():111708. PubMed ID: 34243633
[TBL] [Abstract][Full Text] [Related]
20. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
